Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Rev. mex. cardiol ; 29(3): 134-143, Jul.-Sep. 2018. tab, graf
Article in English | LILACS | ID: biblio-1020712

ABSTRACT

Abstract: Introduction: EuroSCORE is a probabilistic model with good performance in the prognosis of mortality in heart surgery in many latitudes. It is recommendable to validate it in hospitals where it is employed. Objective: To validate the EuroSCORE model in adult patients at the Hospital Regional de Alta Especialidad del Bajío (HRAEB) of León, Guanajuato, Mexico. Material and methods: We conducted an observational transversal, and retrospective study, accomplishing this through the review of the clinical files of patients submitted to heart surgery with and without extracorporeal circulation pump from 01/01/2008 to 12/31/2013 at the HRAEB. This included mortality up to hospital discharge, utilizing the on-line calculator of the EuroSCORE program to estimate risk of death. In order to validate the EuroSCORE model, we assessed discrimination and calibration through the Area Under the receiver operating characteristics (ROC) curve and χ2 test with Hosmer-Lemeshow (H-L) goodness-of-fit, respectively. Results: A total of 342 patients, aged 50.02 ± 16.66 years, 181 males (52.9%) and 161 women (47.1%). The area under the ROC curve of the additive model was 0.763, and of the Hosmer-Lemeshow test was 5.30, with p = 0.62. The area under the ROC curve of the logistic model was 0.761 and of the Hosmer-Lemeshow test, 8.78, with p = 0.36. Conclusion: The EuroSCORE model is a reliable score for estimating the probabilities of death in adult patients submitted to heart surgery with or without the pump at the HRAEB.


Resumen: Introducción: EuroSCORE es un modelo probabilístico con buen desempeño en el pronóstico de mortalidad en cirugía cardiaca en muchas latitudes. Es recomendable validarlo en los hospitales donde se emplea. Objetivo: Validar el modelo EuroSCORE en pacientes adultos en el Hospital Regional de Alta Especialidad del Bajío (HRAEB) de León, Guanajuato, México. Material y métodos: Se realizó un estudio observacional transversal y retrospectivo, que se completó con la revisión de los expedientes clínicos de pacientes sometidos a cirugía cardiaca con y sin bomba de circulación extracorpórea desde el 01/01/2008 hasta el 31/12/2013 en el HRAEB. Esto incluyó la mortalidad hasta el alta hospitalaria, utilizando la calculadora en línea del programa EuroSCORE para estimar el riesgo de muerte. Para validar el modelo EuroSCORE, evaluamos la discriminación y la calibración a través de la curva de características de operación del receptor (ROC) y la prueba de χ2 con la efectividad de ajuste de Hosmer-Lemeshow (H-L), respectivamente. Resultados: Un total de 342 pacientes, de 50.02 ± 16.66 años, 181 hombres (52.9%) y 161 mujeres (47.1%). El área bajo la curva ROC del modelo aditivo fue de 0.763, y la de la prueba Hosmer-Lemeshow fue de 5.30, con p = 0.62. El área bajo la curva ROC del modelo logístico fue 0.761 y de la prueba Hosmer-Lemeshow, 8.78, con p = 0.36. Conclusión: El modelo EuroSCORE es una herramienta confiable para estimar las probabilidades de muerte en pacientes adultos sometidos a cirugía cardiaca con o sin bomba en el HRAEB.


Subject(s)
Humans , Thoracic Surgery/methods , Risk Adjustment , Cross-Sectional Studies , Retrospective Studies , Risk Assessment
2.
Arch. cardiol. Méx ; 75(3): 296-305, jul.-sep. 2005. tab
Article in Spanish | LILACS | ID: lil-631903

ABSTRACT

El objetivo es describir nuestra experiencia, resultados clínicos y angiográficos inmediatos en pacientes con IAM sometidos a angioplastía coronaria transluminal percutánea de rescate (ACTPR). Material y métodos: Tipo de estudio; retrospectivo, observacional, transversal y descriptivo con seguimiento a 30 días. De enero de 2001 a julio de 2004 se realizaron 3,238 procedimientos de ACTP con aplicación de stent a pacientes con diagnóstico de cardiopatía isquémica por aterosclerosis coronaria, se seleccionó a 32 pacientes que representan el 0.98%, con edad de 47 a 79 años promedio de 63, 24 (75%) del sexo masculino, con hipertensión arterial sistémica 29 (90.6%), diabetes mellitus 18 (56.3%), hipercolesterolemia 11 (34.4%), tabaquismo 24 (75%), con antecedentes de angina inestable 9 (28.1%) y con infarto miocardio previo 2 (6.3%). La localización del IAM: anterior extenso 14 (43.8%), anteroseptal en 6 (18.8%), postero-inferior en 5 (15.6%), Pl con extensión eléctrica y/o hemodinámica en VD en 4 (12.5%), lateral en 1 (3.1%). Se trombolizaron en un tiempo promedio 3.19 horas (rango 2-7) con estreptoquinasa 19 (59.4%) y con rTPA 13 (40.6%), la CPK-MB pico (U) promedio de 348 ± 240. Con Killip Kimball (KK) 1 en cinco (15.6%), II 16 (50%), III 5 (15.6%) y IV 6 (18.8%) éstos manejados con balón intraaórtico de contrapulsación. Resultados: Llevados a sala de hemodinamia en un tiempo de 6 a 24 h encontrando flujo TIMI 0 en 16 (50%), TIMI 1 en diez (31.2%), TIMI 2 en seis (18.8%), promedio de vasos enfermos de 1.9. Se implantó stent en 27 (84.3%). Éxito angiográfico post ACTP más stent TIMI 3 en 24 (75%). Complicaciones: En 9(28.1%), en 7 (21.8%) con no reflujo y en 1 (3.1%) disección de la arteria coronaria relacionada con el IAM, 6 (18.7%) que fallecieron, en 4 (12.5%) con choque cardiogénico; 3 (9.3%) la ACTPR fue fallida. Conclusión: La ACTPR es un procedimiento de alto riesgo y pese a ello es una buena alternativa de tratamiento en pacientes con trombólisis fallida.


The present study is aimed at describing the short-term assessment of clinical and angiographic results in patients with acute myocardial infarction treated with rescue percutaneous transluminal coronary angioplasty (RPTCA). Methods: We reviewed retrospectively, from January 2001 to July 2004, the interventional procedures performed in patients with coronary heart disease. From a total of 3,258 patients we selected 32 (0.98%) with acute myocardial infarction and failure of thrombolysis treatment, which were treated with RPTCA to relief the symptoms. Average age was 63 years (range 47-79), there were 24 men (75%); hypertension in 29 (90.6%); diabetes mellitus in 18 (56.3%); currently smoking 24 (75%); dyslipidemia in 11 (34.4%); unstable angina in 9 (28.1%); previous myocardial infarction in 2 (6.3%). The area related to the infarction was anterior and lateral in 14 (43.8%), anteroseptal in 6 (18.8%), postero-inferior in 5 (15.6%) with electric and hemodynamic involvement in 4 (12.5%), lateral in 1(3.1 %). Thrombolysis treatment was delivered in 3.19 hours (range 2-7 hours) with streptokinasein 19 (59.4%) and rTPA in 13 (40.6%). The evaluated serum marker was CPK-MB with the highest level of 348 ± 240 U/L. Killip Kimball (KK) class was established as follows: KKI in 5 (15.6%), II in 16 (50%), III in 5 (15.6%), and IV in 6 (18.8%). Patients with cardiogenic shock were treated with intra-aortic balloon counterpulsation. Results: Time between symptoms and arrival to the cath lab was 11 hours (range 6-24 hours). TIMI flow was: TIMI 0 in 16(50%). TIMI 1 in 10 (31.2%), TIMI 2 in 6 (18.8%). The number of vessels with a significant lesion was 1.9 (range 1-4). Stents were placed in 27 (84.3%) patients. Angiographic success post-angioplasty was achieved in 24 (75%); there were 9 complications (28.1%), no reflow in 7 (21.8%), coronary dissection in 1 (3.1%). Six patients died (18.7%) and 4 of them (12.5%) were in cardiogenic shock. Conclusion: RPT-CA is a high-risk procedure, being an acceptable treatment option for patients with thrombolysis failure.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Angioplasty, Balloon, Coronary , Fibrinolytic Agents/therapeutic use , Myocardial Infarction/therapy , Streptokinase/therapeutic use , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Angioplasty, Balloon, Coronary/mortality , Coronary Angiography , Counterpulsation/methods , Electrocardiography , Fibrinolytic Agents/administration & dosage , Myocardial Infarction/drug therapy , Retrospective Studies , Risk Factors , Stents , Shock, Cardiogenic/therapy , Streptokinase/administration & dosage , Time Factors , Treatment Outcome , Tissue Plasminogen Activator/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL